<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Fri, 17 Jul 2026 02:37:59 -0400--><rss version="2.0">
    <channel>
        <title>Pasithea Therapeutics Corp. (KTTA) Press Releases</title>
        <link>https://ir.pasithea.com/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/pasithea/files/theme/images/logo-sm.png</url>
                <title>Pasithea Therapeutics Corp. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/145/pasithea-therapeutics-announces-participation-in-b-riley</link>
                <pubDate>Wed, 08 Jul 26 07:02:00 -0400</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/145/pasithea-therapeutics-announces-participation-in-b-riley</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/144/pasithea-therapeutics-announces-positive-interim-phase-1</link>
                <pubDate>Tue, 30 Jun 26 07:00:00 -0400</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/144/pasithea-therapeutics-announces-positive-interim-phase-1</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/143/pasithea-therapeutics-announces-amendments-to-clinical</link>
                <pubDate>Tue, 16 Jun 26 07:00:00 -0400</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/143/pasithea-therapeutics-announces-amendments-to-clinical</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/142/pasithea-therapeutics-announces-exhibit-at-childrens</link>
                <pubDate>Mon, 15 Jun 26 07:02:00 -0400</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/142/pasithea-therapeutics-announces-exhibit-at-childrens</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/141/pasithea-therapeutics-announces-orphan-drug-designation-by</link>
                <pubDate>Tue, 02 Jun 26 07:02:00 -0400</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/141/pasithea-therapeutics-announces-orphan-drug-designation-by</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/140/pasithea-therapeutics-announces-appointment-of-kartik</link>
                <pubDate>Mon, 04 May 26 07:01:00 -0400</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/140/pasithea-therapeutics-announces-appointment-of-kartik</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/139/pasithea-therapeutics-announces-grant-of-rare-pediatric</link>
                <pubDate>Mon, 20 Apr 26 07:01:00 -0400</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/139/pasithea-therapeutics-announces-grant-of-rare-pediatric</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/138/pasithea-therapeutics-announces-grant-of-fast-track</link>
                <pubDate>Wed, 01 Apr 26 07:01:00 -0400</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/138/pasithea-therapeutics-announces-grant-of-fast-track</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/137/pasithea-therapeutics-to-present-at-the-oppenheimer-36th</link>
                <pubDate>Tue, 17 Feb 26 07:01:00 -0500</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/137/pasithea-therapeutics-to-present-at-the-oppenheimer-36th</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.pasithea.com/news-events/press-releases/detail/136/pasithea-therapeutics-provides-outlook-on-pas-004-clinical</link>
                <pubDate>Tue, 13 Jan 26 07:01:00 -0500</pubDate>
                <guid>https://ir.pasithea.com/news-events/press-releases/detail/136/pasithea-therapeutics-provides-outlook-on-pas-004-clinical</guid>
                                                                            </item>
            </channel>
</rss>